ERresQ

Executive Summary

ERresQ is a Finnish biopharmaceutical company pioneering a novel therapeutic approach targeting cellular stress and survival pathways. The company has identified compounds that mimic the neurotrophic factors MANF and CDNF, key regulators of cellular stress, inflammation, and immune response. Its pipeline includes repurposed assets (ERQ-01, ERQ-03, ERQ-04) and a new chemical entity (ERQ-02) that specifically target injured or stressed cells, aiming to minimize side effects. ERresQ's therapeutics are designed to treat diabetes, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS) by protecting cells from death and modulating stress responses. Founded in 2020 and based in Helsinki, the company leverages its expertise in small molecules to address significant unmet medical needs in neurodegenerative and metabolic disorders. With a focus on disease-modifying treatments that restore cellular homeostasis, ERresQ offers a differentiated strategy compared to conventional approaches. The company's lead candidates are in preclinical or early clinical stages, with potential to advance into human trials. Key upcoming milestones include the initiation of first-in-human studies for ERQ-02 in Parkinson's disease and the release of preclinical proof-of-concept data for ERQ-01 in diabetes. The company's ability to secure partnerships or funding will be critical for advancing its pipeline. Given the novelty of the MANF/CDNF pathway and the broad applicability across multiple indications, ERresQ represents an attractive opportunity in the biotech space.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 1 clinical trial for ERQ-02 in Parkinson's disease55% success
• Q3 2026Preclinical efficacy data readout for ERQ-01 in diabetes models70% success
• 2026Announcement of strategic partnership or licensing deal for ALS program40% success